Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Maedler, Gitanjali Dharmadhikari, D. Schumann, J. Størling (2009)
Interleukin-1 beta targeted therapy for type 2 diabetesExpert Opinion on Biological Therapy, 9
H. Hoffman, M. Throne, N. Amar, Mohamed Sebai, A. Kivitz, A. Kavanaugh, S. Weinstein, P. Belomestnov, G. Yancopoulos, N. Stahl, S. Mellis (2008)
Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.Arthritis and rheumatism, 58 8
H. Hoffman, S. Rosengren, D. Boyle, J. Cho, J. Nayar, James Mueller, Justin Anderson, A. Wanderer, G. Firestein (2004)
Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonistThe Lancet, 364
H. Koning, MD Bodar, MD Simon, MD Hilst, MD Netea, Jos PhD (2005)
Beneficial response to anakinra and thalidomide in Schnitzler’s syndromeAnnals of the Rheumatic Diseases, 65
Catherine Dostert, V. Petrilli, R. Bruggen, C. Steele, B. Mossman, J. Tschopp (2008)
Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and SilicaScience, 320
A. Thatayatikom, A. Liu (2002)
Mutation of a New Gene Encoding a Putative Pyrin-Like Protein Causes Familial Cold Autoinflammatory Syndrome and Muckle-Wells SyndromePediatrics
KM Hull, I Aksentijevich, HK Singh (2003)
Efficacy of etanercept for the treatment of patients with TNF receptor-associated periodic syndrome (TRAPS) (abstract)Arthritis Rheum, 46
F. Martinon, K. Burns, J. Tschopp (2002)
The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta.Molecular cell, 10 2
A. Wanderer (2009)
Corticosteroid resistance in pulmonary neutrophilic inflammatory disorders and rationale for adjunct IL-1beta targeted therapy.American journal of respiratory cell and molecular biology, 41 2
(2010)
Curr Allergy Asthma Rep
R. Belkhir, L. Moulonguet-Doleris, E. Hachulla, J. Prinseau, A. Baglin, T. Hanslik (2007)
Treatment of familial Mediterranean fever with anakinra.Annals of internal medicine, 146 11
A. Zeft, R. Hollister, Bonnie Lafleur, Prahalad Sampath, J. Soep, Bernadette McNally, G. Kunkel, M. Schlesinger, J. Bohnsack (2009)
Anakinra for Systemic Juvenile Arthritis: The Rocky Mountain ExperienceJCR: Journal of Clinical Rheumatology, 15
F. Martinon, Annick Mayor, J. Tschopp (2009)
The inflammasomes: guardians of the body.Annual review of immunology, 27
P. Piguet, C. Vesin, G. Grau, R. Thompson (1993)
Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica.Cytokine, 5 1
A. So (2008)
Developments in the scientific and clinical understanding of goutArthritis Research & Therapy, 10
B. Faustin, John Reed (2008)
Sunburned skin activates inflammasomes.Trends in cell biology, 18 1
Rongbin Zhou, A. Tardivel, B. Thorens, I. Choi, J. Tschopp (2010)
Thioredoxin-interacting protein links oxidative stress to inflammasome activationNature Immunology, 11
H. Lachmann, I. Koné-Paut, J. Kuemmerle-Deschner, K. Leslie, E. Hachulla, P. Quartier, X. Gitton, A. Widmer, N. Patel, P. Hawkins (2009)
Use of canakinumab in the cryopyrin-associated periodic syndrome.The New England journal of medicine, 360 23
Mathilde Cailliez, F. Garaix, C. Rousset-Rouvière, D. Bruno, I. Koné-Paut, Jacques Sarles, Brigitte Chabrol, Michel Tsimaratos (2006)
Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisisJournal of Inherited Metabolic Disease, 29
R. Terkeltaub, J. Sundy, H. Schumacher, F. Murphy, S. Bookbinder, S. Biedermann, R. Wu, S. Mellis, A. Radin (2009)
The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot studyAnnals of the Rheumatic Diseases, 68
P. Gasse, N. Riteau, S. Charron, Sandra Girre, L. Fick, V. Petrilli, J. Tschopp, V. Lagente, V. Quesniaux, B. Ryffel, I. Couillin (2009)
Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis.American journal of respiratory and critical care medicine, 179 10
Hideki Watanabe, O. Gaide, V. Petrilli, F. Martinon, E. Contassot, S. Roques, J. Kummer, J. Tschopp, L. French (2007)
Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity.The Journal of investigative dermatology, 127 8
井田弘明 (2003)
本邦初のTNF receptor-associated periodic syndrome (TRAPS) の一家系, 43
particular interest, published recently, have been highlighted as: • Of importance
I. Aksentijevich, C. Putnam, E. Remmers, James Mueller, J. Le, R. Kolodner, Zachary Moak, M. Chuang, Frances Austin, R. Goldbach-Mansky, H. Hoffman, D. Kastner (2007)
The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model.Arthritis and rheumatism, 56 4
P. Durez, J. Malghem, B. Lauwerys, F. Houssiau, A. Toukap, G. Depresseux, R. Westhovens, F. Luyten, P. Verschueren (2006)
A prospective one year randomized comparative clinical and MRI study of the effects of methotrexate (MTX) alone or in combination with infliximab (IFX) or intravenous (IV) pulse methylprednisolone (MP) in early rheumatoid arthritis (RA)Annals of the Rheumatic Diseases, 65
E. Drewe, R. Powell, E. McDermott (2007)
Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS).Rheumatology, 46 12
S. Savic, M. McDermott (2009)
Inflammation: Canakinumab for the cryopyrin-associated periodic syndromesNature Reviews Rheumatology, 5
T. Lequerré, P. Quartier, D. Rosellini, F. Alaoui, M. Bandt, O. Mejjad, I. Koné-Paut, M. Michel, E. Dernis, M. Khellaf, N. Limal, C. Job-Deslandre, B. Fautrel, X. Loët, J. Sibilia (2007)
Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in FranceAnnals of the Rheumatic Diseases, 67
H. Hoffman (2009)
Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS).Expert opinion on biological therapy, 9 4
I. Aksentijevich, Seth Masters, Polly Ferguson, P. Dancey, J. Frenkel, Annet Royen-Kerkhoff, R. Laxer, U. Tedgård, Edward Cowen, Tuyet-Hang Pham, M. Booty, D. Jacob, Estes, N. Sandler, N. Plass, Deborah Stone, L. Maria, Turner, S. Hill, J. Butman, R. Schneider, Paul, Babyn, Hatem El-Shanti, E. Pope, K. Barron, X. Bing, A. Laurence, Chyi-Chia Lee, D. Chapelle, Gillian Clarke, K. Ohson, M. Nicholson, M. Gadina, Barbara Yang, Benjamin Korman, Peter Gregersen, P. Hagen, A. Elisabeth, Hak, M. Huizing, D. Douek, Elaine, F. Remmers, Daniel Kastner, R. Goldbach-Mansky (2009)
An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.The New England journal of medicine, 360 23
A Wanderer (2009)
Rationale for IL-1β-targeted therapy to minimize hypoxic-ischemic encephalopathyJournal of Perinatology, 29
Michaela Brenner, T. Ruzicka, Gerd Plewig, Peter Thomas, P. Herzer (2009)
Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin‐1 receptor antagonist anakinraBritish Journal of Dermatology, 161
S. Masters, A. Simon, I. Aksentijevich, D. Kastner (2009)
Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*).Annual review of immunology, 27
R. Panush (2011)
An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonistYearbook of Medicine, 2011
A. Wanderer (2009)
Rationale for IL-1beta targeted therapy for ischemia-reperfusion induced pulmonary and other complications in sickle cell disease.Journal of pediatric hematology/oncology, 31 8
A. Simon, E. Bodar, J. Hilst, J. Meer, T. Fiselier, M. Cuppen, J. Drenth (2004)
Beneficial response to interleukin 1 receptor antagonist in traps.The American journal of medicine, 117 3
Marty Mertens, J. Singh (2009)
Anakinra for Rheumatoid Arthritis: A Systematic ReviewThe Journal of Rheumatology, 36
(2009)
This is an excellent review of inflammasome function
The NLRP3 inflammasome is an intracellular complex that regulates the release of proinflammatory cytokines such as interleukin-1β in response to exogenous pathogens and endogenous danger signals. Evidence from studies involving human genetics, human ex vivo mononuclear cell responses, and in vivo and in vitro murine models confirms the importance of the inflammasome and interleukin-1β in the pathogenesis of several inherited and complex diseases. The availability of several effective interleukin-1β targeted therapies has allowed for successful proof-of-concept studies in several of these disorders. However, many other diseases are likely to be mediated by the inflammasome and interleukin-1β, providing additional targets in the future.
Current Allergy and Asthma Reports – Springer Journals
Published: Apr 28, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.